Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Proflavine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 3/20 | 0.86 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.86 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.86 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.86 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.86 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.86 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.86 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.86 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.86 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.86 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.86 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.86 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.86 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.69 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.86 |
| ▸ | LMNA | P02545 | 3/20 | 0.86 |
| ▸ | HTT | P42858 | 3/20 | 0.86 |
| ▸ | F2 | P00734 | 1/20 | 0.86 |
| ▸ | MAOA | P21397 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proflavine SCHEMBL28534424 | 0.93 | KMT2A (0.90) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL29600097 | 0.93 | KMT2A (1.00) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL27386 | 0.93 | KMT2A (1.00) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL664629 | 0.90 | KMT2A (0.95) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL865664 | 0.90 | KMT2A (0.95) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL10380090 | 0.90 | KMT2A (0.95) | KMT2ALMNAHTTMEN1ACHE | |
| SCHEMBL31473182 | 0.84 | KMT2A (0.82) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL28419396 | 0.84 | KMT2A (0.82) | KMT2ALMNAHTTMEN1ACHE | |
| SCHEMBL5394789 | 0.84 | KMT2A (0.82) | KMT2ALMNAHTTMEN1ACHE | |
| Proflavine SCHEMBL592728 | 0.83 | LMNA (0.72) | KMT2ALMNAHTTMEN1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122056886-A | Application of proflavine and derivative thereof in preparation of METTL B inhibitor | 深圳市人民医院 | 2026-05-19 | — | — | CN | disclosed |
| WO-2021023291-A1 | USE OF PROFLAVINE IN TREATMENT OF LUNG CANCERS | 厦门大学 | 2021-02-11 | — | — | WO | disclosed |
| CN-112336864-A | Application of proflavine in lung cancer treatment | 厦门大学 | 2021-02-09 | — | — | CN | disclosed |
| US-7923204-B2 | Forward mutation assay based on 5-fluorouracil resistance | MERCK SHARP & DOHME CORP. (US) | 2011-04-12 | — | — | US | disclosed |
| EP-1620569-B1 | A FORWARD MUTATION ASSAY BASED ON 5-FLUOROURACIL RESISTANCE | MERCK & CO INC (US) | 2009-12-09 | — | — | EP | disclosed |
| EP-1620569-A4 | A FORWARD MUTATION ASSAY BASED ON 5-FLUOROURACIL RESISTANCE | MERCK & CO INC (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20070042343-A1 | Forward mutation assay based on 5-fluorouracil resistance | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
| EP-1620569-A2 | A FORWARD MUTATION ASSAY BASED ON 5-FLUOROURACIL RESISTANCE | Merck & Co., Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096987-A2 | A FORWARD MUTATION ASSAY BASED ON 5-FLUOROURACIL RESISTANCE | MERCK & CO., INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-5652093-A | Analogues of reporter groups as background reducers in binding assays | APROGENEX, INC. (US) | 1997-07-29 | — | — | US | disclosed |
| US-5501952-A | Analogues of reporter groups as background reducers in hybridization assays | APROGENEX, INC. (US) | 1996-03-26 | — | — | US | disclosed |
| WO-1995002699-A1 | ANALOGUES OF REPORTER GROUPS AS BACKGROUNG REDUCERS IN HYBRIDIZATION ASSAYS | APROGENEX, INC. (US) | 1995-01-26 | — | — | WO | disclosed |